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In isolated rat heart muscle cells, addition of L-alanine (1.5 mmol/l) or of L-valine (3 mmol/l) resulted in either a ca 1.5- or 1.3-fold increase in 
glucose transport, resp. half-maximal stimulation was observed in the presence of L-alanine, but not of L-valine, within a physiological plasmatic 
range of concentrations. D-Alanine (1.5 mmol/1) was ineffective and the stimulating effect of L-alanine could be prevented by an excess of L-serine 
(15-30 mmol/1). L-Alanine produced an increase in 3-O-methyl-D-glucose transport Vmax (from 44.6 to 81.5 pmol's-~.mg protein-l) without affect- 
ing the Km (12.2 in control vs 12.8 mmol/l in alanine-treated cells). Pyruvate (1.5 mmol/1) inhibited glucose transport by 20% and prevented the 
stimulating action of L-alanine (1.5 mmol/1). These results uggest that the effect of L-alanine in cardiac myocytes occurs through the interaction 
with an intracellular site and that both alanine and pyruvate may play a role in the regulation of glucose transport in these cells. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Alanine represents a major gluconeogenic precursor 
for the liver. Numerous lines of evidence indicate that 
this amino acid is specifically released by skeletal [1-4] 
and heart muscle [5] in the fasted state, especially under 
conditions of augmented glucose utilization in these 
tissues [2,6]. We recently found that alanine is, in part, 
responsible for the stimulating effect of partially 
purified samples from a yeast extract on glucose 
transport in isolated cardiac myocytes [7,8]. This obser- 
vation supports the idea that the relevance of alanine in 
carbohydrate metabolism ay not be restricted to its 
release from cardiac and skeletal muscles and subse- 
quent captation by the liver in the fasted state, but may 
also involve a direct effect of this amino acid on a 
peripheral tissue under certain conditions. In this con- 
text, it is of interest to note that alanine is taken up (and 
not released) by skeletal muscle in fed rats [3]. 
Moreover, the exercise-induced release of alanine is 
prevented by an increased glucose availability in 
humans [6]. It was further shown that alanine is a readi- 
ly oxidizable substrate in peripheral tissues [9,10]. The 
aim of the present study was to characterize the 
stimulating action of alanine on glucose transport in 
isolated cardiomyocytes. Further, we examined the 
possible involvement of intracellular pyruvate in this ef- 
fect. The data presented here suggest hat, in car- 
diomyocytes, the uptake of glucose may be regulated by 
products of intermediary metabolism, like alanine and 
pyruvate. 
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2.1. Chemicals 
3-O-methyl-D-Glucose, phloretin and cytochalasin B were purchas- 
ed from Serva (Heidelberg, FRG); all amino acids and pyruvate were 
obtained from Merck (Darmstadt, FRG); 3-O-[3H]methyl-D-glucose 
and 2-deoxy-D-[~H]glucose w re from Amersham (Braunschweig, 
FRG). Silicon oil (Abil AV 200) was from Franken Chemie (Wedel- 
stein, FRG); liquid scintillation fluid (Quickszint 212) was obtained 
from Zinsser (Frankfurt, FRG). Concentrated stock solutions of 
phloretin and cytochalasin B (in dimethylsulfoxide) were prepared as 
appropriate aliquots, stored at - 20°C, and diluted just prior to addi- 
tion to the isolated cardiomyocytes. Final concentrations of 
dimethylsulfoxide were typically 0.02-0.1 °70 in the transport assays 
and did not affect basal transport activity. 
All other chemicals and buffers were freshly prepared immediately 
before use. 
2.2. Isolation of calcium-resistant cardiomyocytes 
Calcium-resistant, rod-shaped cardiomyocytes from adult female 
Sprague-Dawley rats (180-220 g fed ad libitum) were obtained by a 
modification [11] of a method previously described [12]. These cells 
were characterized by a very low basal (i.e. non-stimulated) glucose 
uptake rate, that was increased 8- to 20-fold increase by insulin (10 
nM) [11]. Prior to the experiments, the isolated myocytes were washed 
3 times with assay medium (6 mM KCI, 1 mM Na2HPO4, 0.2 mM 
NaH2PO4, 1.4 mM MgSO4, 128 mM NaCI, 10 mM Hepes, 1 mM 
CaC12, 2°70 bovine serum albumine, fatty acid free, pH 7.4, 37°C, 
equilibrated with oxygen) and resuspended in the same medium at 2-5 
mg cell protein per ml. 
2.3. Determination of 2-deoxy-D-glucose uptake 
1 ml of washed cell suspension was incubated with 0.5 ml of assay 
medium (basal) or of an appropriate dilution of the amino acid to be 
assayed (or pyruvate), in flat-bottomed 20 ml-vials, at 37°C in a shak- 
ing water bath (180 strokes/min, 5 cm/stroke), for 30 rain. The 
transport assay was then started by adding 70 #1 2-deoxy-D- 
[3H]glucose (DOG; 3 #Ci/ml; final sugar concentration: 1.4-2 #M). 
The samples were incubated in the presence of DOG for an additional 
30 min. Subsequently, sugar uptake was stopped by adding 100 ~1 6.8 
mM phloretin (400 #M final concentration); the samples were quickly 
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vortexed, 400 #l-aliquots immediately taken and placed on top of 2 
ml-centrifuge vials containing 1ml silicon oil (density 1.03 g/ml) and 
12 #1 of 35% perchloric acid (on the bottom). These aliquots were 
then centrifuged at10 000 × g for 1 min to separate he cells from the 
less dense incubation medium. The supernatants were removed, the 
tubes cut off and the bottoms (containing the cell pellets) were 
counted in a liquid scintillation counter. Specific, i.e. glucose-carrier- 
mediated DOG uptake was estimated by subtraction of uptake rates 
monitored in the presence of400 #M phloretin from values measured 
in the absence of this inhibitor. 
2.4. Kinetics of 3-O-methyl-D-glucose (3-OMG) uptake 
175 itl washed cardiomyocytes were incubated inthe absence (con- 
trol) or the presence ofalanine (1.5 mM) in a total volume of 275 #1 
in flat-bottomed, 4 ml-tubes, for 30 rain at 37°C in a shaking water 
bath (see above). At the end of this preincubation, 50#1 of a prewarm- 
ed (37°C) solution containing 1.1 #Ci 3-O-[3H]methyl-D-glucose and 
an appropriate amount of unlabelled 3-O-methyl-D-glucose were add- 
ed. The samples were immediately swirled 3-5 times (in about 3 s) and 
shaken for the rest of the assay time (90 s for basal, and 45 s for 
alanine-stimulated c lls) in the water bath (37°C). The assay was ter- 
minated by rapidly adding 100 #1 2.6 mM phloretin (600 t*M final con- 
centration) and vortexing the samples 3times. The cells (of a 300/~l- 
aliquot) were then separated from the incubation mixture as described 
above (DOG-assay). The extent of cell-bound radioactivity at zero 
time was measured in samples pretreated with the specific glucose 
transport inhibitor cytochalasin B (20 #M), in which the assay was 
stopped immediately upon 3-OMG-addition. The carrier-mediated, 
initial transport velocities were calculated by subtracting the uptake 
rates measured in the presence of cytochalasin B (0-420 s) from the 
values obtained in the absence of inhibitor. 
3. RESULTS 
3.1. Effects of L-alanine and L-valine on glucose 
transport 
As previously reported [8], L-alanine and L-valine in- 
crease the rate of 2-deoxy-D-glucose (DOG) uptake in 
calcium-resistant isolated rat cardiomyocytes 1.5- or 
1.3-fold, resp. (Table I). The concentrat ion-dependence 
of these effects is shown in Fig. 1. Hal f -maximal 
st imulat ion was observed at approximately 0.2 mmol/1 
Table I 
Effect of L-alanine, D-alanine and L-valine on basal 2-deoxy-D- 
glucose transport and influence of an excess of L-serine on L-alanine- 
induced transport stimulation 
Addition 2-deoxy-D-glucose transport 
rate (%0 of basal) 
None (basal) 100 + 10 
L-alanine (1.5 mM) 151 + 9 
D-alanine (1.5 mM) 92 ___ 11 
L-serine (15 mM) 92 + 7 
L-serine (15 mM) + L-alanine 119 _+ 7 
L-serine (30 mM) 109 _+ 7 
L-serine (30 mM) + L-alanine 102 ___ 15 
L-valine (3 mM) 130 + 12 
L-valine (3 mM) + L-alanine 137 + 13 
DOG transport was measured incardiomyocytes previously exposed 
(30 min, 37°C) to one or two amino acids, as indicated. For samples 
with both L-serine and L-alanine, the ceils were incubated for 2 min 
with L-serine prior to L-alanine addition. Values represent relative 
uptake (as compared to 100%0 in basal cells). Data are means from 2 
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Fig. I. Concentration dependence of the effect of L-alanine and L- 
valine on 2-deoxy-D-glucose transport. Data are expressed aspercen- 
tage of the maximal effect induced by the corresponding amino acid 
in each experiment; L-alanine ([]) and L-valine (,). Data are means 
(_+SE) from at least 2 separate xperiments (each experiment in
triplicate). 
with alanine and 0.6-0.7 mmol / l  with valine. In- 
terestingly, alanine is effective in a range of concentra- 
t ions (0.05-1 mmol/1) that corresponds to values 
measured in plasma samples of rats [3,9,13], dogs [14] 
and humans [1,2,5,15]. In contrast, the valine concen- 
trations necessary to elicit a significant st imulation of 
glucose transport (0.3-1.5 mmol / l )  lie above the 
physiological values in rats [16] and humans [2,5,15]. 
Further,  the effects of alanine and valine are not ad- 
ditive (Table I). No significant changes in basal glucose 
transport  could be detected in the presence of the other 
branched-chain amino acids L-leucine or L-isoleucine 
(0.5-10 mmol/1) (not shown). 
3.2. Effects of  D-alanine on basal glucose transport 
and of L-serine on L-alanine-induced stimulation 
We next addressed the question as to whether L- 
alanine has to be taken up by the cardiomyocytes to in- 
duce its stimulating effect on glucose transport in these 
cells. The isomer D-alanine, that does not penetrate in- 
tact cells (owing to the stereospecificity of amino acid 
transport  systems), had no detectable influence on 
DOG transport at a concentrat ion (1.5 mmol /1)  at 
which the natural  L-isomer is maximally effective 
(Table I). As L-serine and L-alanine enter mammal ian  
cells via a common amino acid transport system (the so- 
called ASC-system; [17]), an excess of one of these 
amino acids should inhibit the uptake of the other one. 
As shown in Table I, a large excess of L-serine (15-30 
mmol / l )  suppressed the effect of 1.5 mmol / l  L-alanine. 
3.3. Kinetics of 3-O-methyl-D-glucose transport in 
alanine-stimulated cardiomyocytes 
To further characterize the action of alanine on 
glucose transport,  we determined the kinetic parameters 
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Fig. 2. Hanes plot of 3-O-methyl-D-glucose transport kinetics in basal 
and alanine-stimulated c lls. The cytochalasin-B-sensitive, nitial rate 
of 3-O-methyl-D-glucose uptake was determined at the concentra- 
tions indicated, inthe absence (basal, B) or in the presence of1.5 mM 
L-alanine (m). Each point represents the mean of at least 2 separate 
experiments (n = 7 in each experiment). 
of the uptake of the non-metabolizable glucose analog 
3-O-methyl-D-glucose (3OMG) in basal (i.e. non- 
stimulated) and alanine-stimulated cardiomyocytes. 
Vmax and Km values were calculated by linear regression 
of data (initial 3OMG uptake) transformed in a Hanes 
plot (Fig. 2). Alanine (1.5 mmol/ l)  raised the maximal 
transport velocity from 44.6 (basal) to 81.5 pmol 
30MG. s - 1. mg protein-  1, without significantly affec- 
ting the gm (12.18 in basal vs 12.84 mmol/1 in alanine- 
treated cells). 
3.4. Effect of pyruvate on basal and alanine-stimulated 
glucose transport 
In order to investigate the possible involvement of in- 
tracellular pyruvate in the stimulation observed upon 
alanine addition, we tested the effect of pyruvate (1.5 
mmol/ l )  (that is readily taken up by cardiac tissue; [18]) 
added alone or in combination with alanine (1.5 
mmol/ l ) ,  on the uptake of 2-deoxy-D-glucose. The data 
presented in Table II clearly show that pyruvate not on- 
Table II 
Effect of pyruvate on basal and alanine-stimulated 2-deoxy-D-glucose 
transport 
Addition 2-deoxy-D-glucose transport 
rate (07o f basal) 
None (basal) 100 + 11 
L-alanine (1.5 mM) 140 + 7 (**) 
Pyruvate (1.5 mM) 81 _+ 9 (*) 
Pyruvate + alanine 79 + 8 (*) 
DOG transport was measured in cardiomyocytes previously exposed 
(30 rain, 37°C) to the agents, as indicated. Data represent relative 
transport, as compared to 100°70 basal. Values are means from 2 in- 
dependent experiments. (*) Values are significantly different from 
basal at the 0.507o level; (**) at the 0.1070 level (calculated with Stu- 
dent's t-test). 
ly significantly inhibits basal DOG transport but also 
prevents the stimulating effect of alanine. Further, 
alanine did not produce a detectable change in the total 
intracellular pyruvate content (not shown). 
4. DISCUSSION 
The role of alanine, released by skeletal [1-4] and 
heart [5] muscles in the fasted (but not in the fed state; 
[3]), as an essential precursor for hepatic 
gluconeogenesis is well-established [19]. Our observa- 
tion that this amino acid stimulates glucose transport in 
cardiac myocytes (a step that is likely to be limiting for 
glucose metabolism) possibly reflects a new regulatory 
mechanism in carbohydrate metabolism of a peripheral 
tissue. 
The fact that alanine is effective at concentrations 
that correspond to the physiological range in the plasma 
of mammals (Fig. 1 and [1-3,5,13-15] supports the idea 
that the effect we now observed may be of physiological 
relevance. Interestingly, it was recently reported that 
alanine inhibits the uptake and oxidation of glucose in 
isolated brown adipocytes [20]. This and our finding in- 
dicate that alanine may exert tissue-specific effects. 
The action of valine was less pronounced than that of 
alanine (Table I). Moreover, valine only produced an 
increase in glucose transport at concentrations that 
markedly exceed the plasma values measured in rats 
[16] and humans [2,5,15]. The finding that alanine and 
valine do not act additively (Table I), along with the 
fact that branched-chain amino acids are the major 
source of nitrogen for pyruvate transamination 
[4,21-24] suggest that the effect of valine may be secon- 
dary to alanine formation in myocytes. However, the 
other branched-chain amino acids leucine and 
isoleucine failed to induce a significant stimulation of 
glucose transport in cardiomyocytes (unpublished 
observation). Thus, the metabolic basis of the valine ef- 
fect remains to be clarified. 
The results presented in Table I further demonstrate 
that alanine has to be taken up by the cardiomyocytes 
to elicit its effect. However, the alanine-induced 
stimulation is unlikely to involve the sodium influx con- 
comitant to the alanine uptake, since serine, that is 
taken up via the same sodium-dependent amino acid 
carrier as alanine [17], had no effect on glucose 
transport (Table I). 
The fact that alanine alters the Vmax, but not the gm, 
of glucose transport (Fig. 2) makes a direct interaction 
of this amino acid with glucose carriers unlikely, since 
a higher maximal transport velocity must involve either 
a larger number of functional carriers in the plasma 
membrane or a higher intrinsic activity of these carriers. 
Assuming that a high alanine uptake rate may also lead 
to an increase in the intracellular pyruvate concentra- 
tion, we directly assayed the effect of pyruvate addition 
on glucose transport. Surprisingly, this metabolite 
129 
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significantly inhibited the uptake of glucose and com- 
pletely suppressed the stimulating action of alanine 
(Table II). Furthermore, no change in the total in- 
tracellular pyruvate concentration could be detected 
upon alanine addition (not shown). These findings are 
compatible with two types of explanations. The first 
possibility is that alanine and pyruvate modulate 
glucose transport independently, the former being 
stimulatory and the latter inhibitory. However, the ad- 
vantage of this dual regulation is not easily conceivable 
since concentration changes of one of these metabolites 
should readily affect he concentration f the other one, 
owing to the high alanine aminotransferase (EC 
2.6.1.2.) activity present in muscle tissue [25]. 
Alternatively, alanine and pyruvate may modulate 
some kind of metabolic signal via a common pathway, 
but in an antagonistic manner. They may, for instance, 
influence the flux through the cytosolic malate 
dehydrogenase (EC 1.1.1.37.) via transamination reac- 
tions involving the alanine aminotransferase and the 
aspartate aminotransferase (EC 2.6.1.1.) [4]. Thus, 
alanine would raise and pyruvate would lower the 
cytosolic NADH/NAD ratio. In adipocytes, alanine 
was indeed shown to increase the cellular glutamate and 
aspartate and decreases the malate and a-ketoglutarate 
levels [26]. Changes in the cytosolic redox potential 
may, in turn, represent a signal for glucose transport 
regulation. 
Further investigations will be required to examine 
these different possibilities. Nevertheless, our present 
results uggest that, in cardiac muscle cells, some form 
of metabolic oupling may exist between pyruvate and 
alanine, on one hand, and glucose transport, on the 
other hand. 
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